58
Participants
Start Date
November 1, 2017
Primary Completion Date
November 17, 2023
Study Completion Date
November 27, 2023
Blinded study medication
Blinded study medication: This is a double-blind within-subject Phase II trial. Study medications will remain blinded. Participants may receive a dose of medication from one or more of the following categories: prescription stimulants, prescription benzodiazepines, prescription opioids, prescription cannabinoids, over-the-counter medications or placebo (sugar pill). All subjects will serve as their own control. Study medication administration will be randomized within each participant.
Johns Hopkins, Baltimore
National Institute on Drug Abuse (NIDA)
NIH
Johns Hopkins University
OTHER